10.1 North American Pit Vipers (Crotalinae): Envenomation Assessment and Antivenom Management

Venomous snakebites in North America represent high-stakes clinical emergencies requiring rapid diagnostic evaluation, rigorous monitoring of hematologic and tissue parameters, and aggressive antidotal pharmacotherapy. The vast majority of native venomous snakebites in the United States (greater than 95%) are inflicted by pit vipers belonging to the family Viperidae, subfamily Crotalinae. For the specialist in poison information, managing these complex envenomations requires distinguishing true venom inoculation from dry bites, evaluating the triad of local, hematologic, and systemic toxicity, selecting appropriate antivenom dosing regimens, and anticipating delayed recurrent coagulopathy.

---

Taxonomy, Morphology, and Venom Inoculation

North American crotalines are divided into three medically significant genera:

1. Crotalus: True rattlesnakes, including the Eastern diamondback (Crotalus adamanteus), Western diamondback (Crotalus atrox), Timber rattlesnake (Crotalus horridus), and Mojave rattlesnake (Crotalus scutulatus). These species are responsible for the most severe clinical envenomations, profound coagulopathies, and fatalities.
2. Sistrurus: Pygmy rattlesnakes (Sistrurus miliarius) and massasaugas (Sistrurus catenatus), which possess small rattles and typically deliver lower venom volumes.
3. Agkistrodon: Copperheads (Agkistrodon contortrix) and cottonmouths or water moccasins (Agkistrodon piscivorus). Copperhead bites are the most common snakebites in the southeastern and mid-Atlantic regions, causing substantial local tissue injury but rare life-threatening systemic toxicity.

Morphological Characteristics of Pit Vipers vs. Harmless Colubrids

Reliable physical identification distinguishes pit vipers from non-venomous colubrid snakes (such as garter snakes, black racers, and water snakes):

CLINICAL PEARL: Loreal Pits and Solenoglyphous Dentition The loreal pit is a specialized infrared receptor innervated by the trigeminal nerve that can detect thermal fluctuations as minute as 0.003°C. Pit vipers possess solenoglyphous dentition—large, canaliculated fangs mounted on rotatable maxillae that swing forward 90 degrees during a strike, acting as hypodermic needles to inject venom deep into subcutaneous tissue or muscle.

Dry Bites

Approximately 20% to 25% of all pit viper strikes are 'dry bites', wherein the snake strikes defensively but injects no venom due to conscious contraction of the compressor glandulae muscles. An envenomation cannot be diagnosed based solely on fang punctures; the patient must exhibit objective local tissue changes (erythema, progressive edema, ecchymosis), laboratory coagulopathy, or systemic symptoms. An asymptomatic patient with puncture wounds must be monitored with serial physical exams and laboratory studies for a minimum of 8 to 12 hours post-bite before an exposure can be deemed a true dry bite.

---

Pit Viper Venom Pathophysiology and the Envenomation Triad

Crotaline venom is a complex, multi-component enzymatic cocktail containing over 50 distinct bioactive proteins, enzymes, and non-enzymatic polypeptides designed to immobilize prey and initiate pre-digestive tissue liquefaction.

Venom Inoculation ──> SVMPs & Hyaluronidase ──> Capillary Breakdown & Microvascular Extravasation (Edema, Blebs)
                  ──> Serine Proteases    ──> Fibrinogen Consumption & Platelet Destruction (VICC)
                  ──> PLA2 Enzymes        ──> Myonecrosis, Hemolysis & Neurotoxicity (Mojave Toxin)
                  ──> Systemic Peptides   ──> Kinin Release, Capillary Leak, Vasodilation & Shock

Biochemical Mediators of Venom Injury

• Snake Venom Metalloproteinases (SVMPs): Zinc-dependent enzymes that hydrolyze basal lamina proteins (type IV collagen, laminin, fibronectin) anchoring vascular endothelial cells. This causes widespread microvascular rupture, capillary leak, massive extravasation of plasma and red blood cells, severe edema, blistering, and local tissue necrosis.
• Snake Venom Serine Proteases (SVSPs): Thrombin-like enzymes (such as crotalase and ancrod) that directly cleave fibrinogen into friable, non-functional fibrin monomers. Unlike physiological thrombin, these enzymes do not activate factor XIII; consequently, the uncrosslinked fibrin polymers are immediately broken down by endogenous plasmin, causing profound hypofibrinogenemia, elevated D-dimer, and elevated PT/INR without microvascular thrombosis. This process is termed Venom-Induced Consumptive Coagulopathy (VICC).
• Phospholipase A2 (PLA2): Hydrolyzes cell membrane phospholipids, disrupting myofibril integrity to produce local and systemic myonecrosis (rhabdomyolysis) and intravascular hemolysis.
• Neurotoxic PLA2 Complexes (Mojave Toxin): Found in Crotalus scutulatus (Mojave rattlesnake Type A venom). Mojave toxin is a heterodimeric presynaptic neurotoxin that blocks voltage-gated calcium channels, inhibiting acetylcholine exocytosis at somatic motor endplates. Mojave rattlesnake envenomations characteristically present with minimal to no local tissue swelling and no coagulopathy, but trigger delayed cranial nerve palsies, ptosis, dysarthria, and respiratory failure.
• C-Type Lectins: Bind directly to platelet surface receptors (such as GPIb and GPVI), inducing platelet activation, aggregation, and rapid clearance, precipitating profound thrombocytopenia.

The Clinical Envenomation Triad

1. Local Tissue Injury: Intense, immediate local burning pain at the puncture site followed by progressive, non-pitting edema that extends proximally toward the trunk. Petechiae, spreading ecchymosis, lymphangitis, and serosanguinous or hemorrhagic bullae (blebs) emerge over 6 to 24 hours. Severe envenomation produces local dermonecrosis and deep muscle liquefaction.
2. Hematologic Derangements (VICC): Uncontrolled consumption of coagulation factors manifesting as severe hypofibrinogenemia (<100 mg/dL or undetectable), severe thrombocytopenia (<50,000 to 100,000/mcL), prolonged prothrombin time (PT) and International Normalized Ratio (INR), and markedly elevated fibrin degradation products / D-dimer. Clinical bleeding manifests as oozing from puncture wounds and IV sites, gingival bleeding, epistaxis, hematuria, gastrointestinal hemorrhage, and potentially fatal intracranial hemorrhage.
3. Systemic Manifestations: Vasodilatory shock and hypotension driven by venom kininogens releasing bradykinin and histamine; diaphoresis, nausea, protracted vomiting, and diarrhea; a distinct metallic, rubbery, or minty taste in the mouth (dysgeusia); circumoral and peripheral paresthesias; and coarse muscle fasciculations or myokymia (rippling muscle contractions beneath the skin, particularly around the face, neck, and shoulders).

---

Antivenom Pharmacotherapy: CroFab vs. Anavip

Modern antivenom therapy in the United States utilizes purified antibody fragments to neutralize circulating and tissue-bound venom components while minimizing the incidence of immediate acute hypersensitivity and delayed serum sickness.

Pharmacologic Comparison: CroFab vs. Anavip

Indications for Antivenom Administration

Antivenom is indicated whenever an envenomation exhibits signs of progression beyond minor, localized puncture findings:

• Progressive Local Swelling: Swelling that crosses a major anatomical joint (e.g., wrist, elbow, ankle, knee) or extends rapidly (>2.5 cm or 1 inch per hour along the extremity).
• Significant Coagulopathy: Platelet count <100,000/mcL, serum fibrinogen <100 mg/dL, elevated INR >1.5, or any active clinical bleeding.
• Systemic Toxicity: Hemodynamic instability (hypotension, shock), angioedema or airway swelling, intractable vomiting, severe neurotoxicity, or prominent fasciculations/myokymia.

Achieving and Defining Initial Control

Initial resuscitation centers on halting venom progression through aggressive IV antivenom titration:

Assess Patient ──> Indications Met? ──> Administer Initial Dose (CroFab 4–6 vials OR Anavip 10 vials)
      │
      └──> Reassess at 1 Hour Post-Infusion:
             1. Swelling progression halted? (Check ink marks on limb)
             2. Coagulopathy stable or improving? (Fibrinogen >100, Platelets >100k)
             3. Systemic symptoms resolved? (Normotensive, vomiting ceased)
                   ├── YES ──> INITIAL CONTROL ACHIEVED ──> Maintenance Protocol
                   └── NO  ──> REPEAT FULL LOADING DOSE (CroFab 4–6 vials OR Anavip 10 vials)

1. Baseline Preparation: Mark the leading edge of swelling, erythema, and tenderness with an indelible skin marker every 15 to 30 minutes. Measure limb circumferences at standardized anatomical landmarks (e.g., 10 cm above and below the patella or olecranon). Obtain baseline CBC, platelet count, PT/INR, fibrinogen, D-dimer, CK, and comprehensive metabolic panel.
2. Loading Infusion: Reconstitute the vials in 250 mL of normal saline. Begin the infusion slowly (25 to 50 mL/hour for the first 10 minutes) to observe for acute anaphylactic reactions; if no adverse reaction occurs, increase the rate to complete the full infusion within 60 minutes.
3. Reassessment for Initial Control: Initial control is defined as the arrest of local swelling progression, stabilization or upward trend in hematologic parameters, and complete resolution of systemic symptoms. If progression persists at 1 hour post-infusion, repeat the full initial dose (an additional 4 to 6 vials of CroFab or 10 vials of Anavip). Repeat until initial control is documented.
4. Post-Control Maintenance:
   • CroFab: Administer 2 vials IV at 6, 12, and 18 hours after initial control is achieved (total of 6 maintenance vials).
   • Anavip: Do NOT administer scheduled maintenance infusions. Re-examine the patient every 2 to 4 hours; administer repeat doses of 10 vials only if swelling resumes progression, coagulopathy worsens, or systemic symptoms recur.

---

Delayed Recurrent Coagulopathy and Post-Discharge Surveillance

A critical phenomenon in crotaline toxicology is delayed recurrent coagulopathy, which occurs in up to 30% to 50% of patients treated with CroFab.

Mechanism of Recurrence

During a bite, venom is deposited deep into poorly vascularized subcutaneous and muscular tissues, forming an insoluble tissue antigen depot. This venom depot leaches slowly into the lymphatic and systemic circulation over 5 to 14 days. Meanwhile, the monovalent Fab fragment (CroFab) has an elimination half-life of only 12 to 15 hours and is rapidly cleared by renal glomerular filtration. Once circulating Fab concentrations plummet, un-neutralized venom leaking from the tissue depot triggers a resurgence of VICC, typically presenting 2 to 7 days post-treatment.

Because Anavip possesses a much larger divalent F(ab')2 structure with an extended half-life of ~133 hours, it remains in the vascular and interstitial space for days, neutralizing depot venom and drastically reducing the incidence of late recurrent coagulopathy.

Monitoring and Discharge Protocol

• Inpatient Observation: Patients achieving initial control must be observed in the hospital for a minimum of 18 to 24 hours after the last dose of antivenom. Discharge criteria require stable limb measurements, no active bleeding, normal or improving coagulopathy markers, and stable vital signs.
• Mandatory Follow-up Testing: All patients treated with CroFab must have repeat coagulation panels (platelets, PT/INR, fibrinogen) drawn at 48 to 72 hours and again at 5 to 7 days post-discharge.
• Treatment of Recurrence: If outpatient follow-up reveals severe recurrent thrombocytopenia (<20,000 to 25,000/mcL), severe hypofibrinogenemia (<50 to 100 mg/dL), or any active bleeding, the patient must be immediately readmitted and retreated with antivenom (CroFab 4 to 6 vials or Anavip 10 vials). Platelet or fresh frozen plasma (FFP) transfusions are not a substitute for antivenom in venom-induced coagulopathy, because circulating venom rapidly consumes the transfused products; they are reserved for life-threatening bleeding and given together with antivenom.

---

Prohibited First-Aid Interventions and the Compartment Syndrome Controversy

Outdated lay interventions and aggressive surgical approaches cause severe harm and must be firmly intercepted by poison specialists.

Prohibited Out-of-Hospital First Aid

PROPER FIRST-AID PROTOCOL: Immediately move out of the snake's striking range. Keep the patient calm. Immediately remove all constricting rings, bracelets, watches, and tight clothing from the bitten extremity before edema develops. Splint and immobilize the limb in a neutral, functional position at or slightly below heart level. Transport the patient immediately to the nearest emergency department capable of administering antivenom.

The Fasciotomy Controversy: True Compartment Syndrome vs. Pseudocompartment Syndrome

Crotaline envenomations characteristically produce severe subcutaneous edema, tense dermal ecchymosis, and excruciating pain that mimics acute compartment syndrome. However, true intracompartmental hypertension (>30 to 40 mmHg) is exceptionally rare (occurring in <1% to 2% of cases) because venom is typically injected into superficial subcutaneous fat rather than deep fascial compartments.

Performing an emergent fasciotomy in a coagulopathic pit viper victim causes catastrophic, life-threatening hemorrhage, intractable wound infection, permanent muscle herniation, chronic disabling edema, and loss of limb function. Therefore, fasciotomy is almost never indicated.

Protocol for Suspected Compartment Syndrome

1. Administer Additional Antivenom: The primary cause of elevated tissue pressure is venom-mediated capillary permeability. Administer an immediate additional full loading dose of antivenom (CroFab 4 to 6 vials or Anavip 10 vials) and elevate the limb to heart level.
2. Direct Intracompartmental Pressure Measurement: Never diagnose compartment syndrome based on physical exam alone. Directly measure compartment pressures using an intracompartmental pressure monitor (e.g., Stryker needle).
3. Surgical Criteria: Emergent fasciotomy is contemplated ONLY if intracompartmental pressure remains consistently elevated above 30 to 40 mmHg (or if the delta pressure [diastolic blood pressure minus compartment pressure] is <30 mmHg) despite high-dose antivenom administration, limb elevation, and mannitol/fluid optimization over a 4- to 6-hour window.